Tresiba Overdose & Accidental Excess Dose: What Every Woman Needs to Know

What Happens When You Take Too Much Tresiba

Too much insulin degludec causes blood glucose to drop below safe levels. That is the core danger. What makes an insulin degludec overdose distinctly more dangerous than overdose with short-acting insulin is the drug's pharmacokinetics: its half-life is approximately 25 hours, and steady-state glucose-lowering effect extends across a full 24-hour period or longer 1. A single excess dose can produce hypoglycemia that does not peak for several hours and then persists well beyond what families and even clinicians expect.

Why Duration Matters More Than Peak

With regular insulin, hypoglycemia tends to peak within 2-4 hours and resolve. With insulin degludec, the glucose-lowering action is flat and prolonged rather than peaked, which means you may feel mildly low for hours before glucose crashes further. Patients who eat a snack, feel temporarily better, and go to sleep are at serious risk because the drug is still working while they rest. Nocturnal hypoglycemia is precisely where DEVOTE showed insulin degludec's clinical advantage over glargine, but that same flat nocturnal profile becomes a liability in overdose.

The Pharmacology Behind the Risk

Insulin degludec forms multi-hexamer chains after subcutaneous injection. These chains depot slowly in the tissue and release insulin monomers in a sustained, low-variance stream 1. The result is a coefficient of variation for glucose-lowering effect of approximately 20%, compared to 48% for insulin glargine U-100 2. Predictability is an advantage therapeutically. In overdose, it means there is a large subcutaneous depot that cannot be removed, and glucose-lowering will continue until that depot is exhausted.

Recognizing an Overdose: Symptoms to Act On Now

Symptoms of hypoglycemia from any cause follow a recognizable pattern, but the timeline with insulin degludec is stretched.

Early Symptoms (Blood Glucose Roughly 54-70 mg/dL)

• Shakiness, trembling
• Sweating without exertion
• Heart pounding or racing
• Irritability or sudden mood shift
• Intense hunger
• Pale skin

Severe Symptoms (Blood Glucose Below 54 mg/dL)

• Confusion, slurred speech
• Inability to swallow safely
• Seizure
• Loss of consciousness

If you or someone near you cannot swallow or is unconscious, do not give food or juice by mouth. Call 911 immediately. Glucagon (nasal or injectable) should be given while waiting for emergency services 3.

Immediate Steps: What to Do Right Now

Act in this order.

1. Check blood glucose if a meter is available. Do not delay calling for help while searching for a meter.
2. Call 911 if the person is unconscious, seizing, or cannot swallow.
3. Call Poison Control (1-800-222-1222) if the person is conscious and can swallow. They will guide you through glucose intake and monitoring intervals.
4. Give 15-20 grams of fast-acting carbohydrate (4 glucose tablets, 4 oz juice, or regular soda, not diet) if the person is awake and can swallow safely 4.
5. Recheck glucose in 15 minutes. Repeat carbohydrate if still below 70 mg/dL.
6. Do not leave the person alone. Because of insulin degludec's 25-hour half-life, hypoglycemia can recur after initial treatment.
7. Go to the emergency department. Any significant excess dose warrants IV dextrose infusion and monitored observation for at least 12-24 hours 5.

Glucagon: Know Where Yours Is Before an Emergency

Glucagon kits or nasal glucagon (Baqsimi) should be kept accessible by anyone using insulin. Nasal glucagon 3 mg is as effective as injected glucagon for severe hypoglycemia 6 and requires no mixing. Tell your household members and close contacts where it is stored and how to use it.

How Tresiba Works: The Mechanism Behind the Ultra-Long Action

Understanding the mechanism helps you understand why overdose management differs from other insulins.

Multi-Hexamer Depot Formation

After subcutaneous injection, insulin degludec molecules associate into long chains of hexamers attached to fatty acids (C16 diacid) via a glutamic acid linker. These chains form an insoluble depot at the injection site. From that depot, individual insulin monomers dissociate slowly into capillaries, producing a flat, peakless insulin profile 1.

Clinical Consequence: No Peak, No Easy Off-Switch

Rapid-acting insulins can be partially managed with carbohydrates timed to their peak. Insulin degludec has no meaningful peak. Its glucose-lowering effect across 24 hours is nearly uniform 2. In overdose, this creates a sustained glucose drain that requires sustained glucose replacement, typically intravenous dextrose in a clinical setting.

DEVOTE Trial Context

The DEVOTE trial (NEJM 2017) randomized 7,637 people with type 2 diabetes at high cardiovascular risk to insulin degludec or glargine U-100. Insulin degludec was non-inferior to glargine on major adverse cardiovascular events. Severe hypoglycemia occurred in 4.9% of the degludec group versus 6.6% of the glargine group (rate ratio 0.73, 95% CI 0.60-0.89). Nocturnal severe hypoglycemia was 27% lower with degludec. These findings reflect therapeutic use. In overdose, the advantage of a lower hypoglycemia rate at therapeutic doses does not translate into a shorter or less severe hypoglycemic episode if an excess dose is taken.

Women-Specific Risks: How Your Hormones Change the Picture

Women are not a homogeneous group for insulin sensitivity. Estrogen, progesterone, cortisol, and the hormonal shifts of the menstrual cycle, pregnancy, and menopause each change insulin requirements. This means the same dose can be an overdose at one point in your cycle and inadequate two weeks later.

Reproductive Years: The Menstrual Cycle and Insulin Sensitivity

Insulin sensitivity fluctuates across the cycle. During the follicular phase (roughly days 1-14), estrogen tends to increase insulin sensitivity, meaning your normal dose may act more strongly than expected 7. During the luteal phase (days 15-28), rising progesterone decreases insulin sensitivity, so women with type 1 diabetes often need higher doses. The clinically dangerous transition is at menstruation, when progesterone drops sharply and insulin resistance falls: a luteal-phase dose that was appropriate becomes a relative overdose.

Tracking your cycle alongside your glucose data is not optional if you use basal insulin. It is basic safety practice.

Perimenopause

Perimenopause brings erratic estrogen swings that can destabilize glucose control in both directions. Women who have used a stable Tresiba dose for years may find that fluctuating estrogen shifts their insulin requirement week to week 8. A dose that was safe last month can produce hypoglycemia this month without any change in diet or activity. Discuss a monitoring plan and possible dose adjustment strategy with your prescriber as you enter perimenopause.

Postmenopause

After menopause, declining estrogen is associated with increased visceral adiposity and insulin resistance in many women, which may mean higher insulin requirements. Hypoglycemia unawareness (the loss of early warning symptoms) also increases with age and with longer duration of diabetes. Women post-menopause who take insulin degludec are at particular risk for severe, unrecognized nocturnal hypoglycemia 9.

PCOS

Women with polycystic ovary syndrome have baseline insulin resistance and sometimes use insulin as part of complex diabetes management. Because PCOS is itself a state of metabolic variability, any change in body weight, stress, or hormonal treatment can shift insulin sensitivity enough to turn a formerly safe dose into an excess dose.

Pregnancy and Lactation Safety

Pregnancy

Insulin degludec does not carry a traditional FDA letter category because it was approved after the FDA moved to the new labeling system in 2015. Available human data are limited. The label notes that animal studies showed embryofetal toxicity at doses producing maternal hypoglycemia, which is the expected risk mechanism for any insulin in overdose during pregnancy 10.

The critical point: insulin does not cross the placenta in meaningful amounts. The danger to the fetus from insulin overdose during pregnancy is maternal hypoglycemia, which reduces placental glucose delivery and can cause fetal distress 11. Severe or prolonged maternal hypoglycemia has been associated with fetal bradycardia and, in extreme cases, intrauterine death.

ACOG Practice Bulletin 201 on pregestational diabetes recommends that blood glucose targets during pregnancy be maintained without significant hypoglycemia, and that basal insulin choices be individualized. Many practitioners in the US continue patients on insulin degludec if they are well controlled on it, though NPH has the longest safety record in pregnancy. This is a decision to make with your OB and endocrinologist together, not alone.

Insulin requirements change dramatically across trimesters. In the first trimester, nausea and reduced food intake can cause hypoglycemia from a previously appropriate dose. In the second and third trimesters, placental hormones increase insulin resistance substantially, sometimes requiring dose increases of 50-100%. Any dose increase raises the risk of rebound overdose if eating is disrupted.

Postpartum

Insulin requirements drop sharply within hours of delivery as placental hormones disappear. Women who do not reduce their basal insulin dose immediately postpartum are at high risk of severe hypoglycemia in the first 48 hours 11. Because insulin degludec's action persists for 24-plus hours, there is no fast way to reduce its effect. This transition should be planned in advance with your care team, with a written postpartum dose reduction protocol in hand before delivery.

Lactation

Insulin is a large peptide that does not transfer into breast milk in clinically meaningful amounts 12. What does transfer into milk is glucose, so hypoglycemia in a breastfeeding mother can briefly affect milk composition but does not directly expose the infant to insulin. Breastfeeding is compatible with insulin degludec. Breastfeeding itself lowers blood glucose (caloric drain), which means hypoglycemia risk is modestly higher during nursing sessions. Keeping fast-acting carbohydrate nearby when breastfeeding is practical risk reduction.

Contraception

Insulin degludec is not a teratogen in the direct chemical sense, but maternal hypoglycemia in the first trimester carries risks of spontaneous abortion and fetal developmental effects. Women of reproductive age using insulin degludec who are not planning pregnancy should use reliable contraception and discuss their contraceptive options with their provider.

Who This Is Right For and Who Should Take Extra Precautions

Well-Suited

• Women with type 1 or type 2 diabetes who have predictable schedules and can maintain consistent injection timing
• Women post-menopause with stable insulin requirements
• Women who experienced nocturnal hypoglycemia on insulin glargine (DEVOTE showed a 27% reduction in nocturnal severe hypoglycemia 13)

Extra Caution Warranted

• Pregnant women, particularly in the first trimester and immediately postpartum, because the steep dose changes during these periods create overdose risk
• Women in perimenopause with erratic estrogen and unpredictable insulin sensitivity shifts
• Women with hypoglycemia unawareness, regardless of life stage
• Women with eating disorders or irregular food intake, where caloric unpredictability makes any long-acting insulin harder to dose safely
• Women with renal impairment (creatinine clearance <30 mL/min), because reduced insulin clearance prolongs hypoglycemia duration 10

How Overdose Is Managed in the Emergency Department

Emergency management of insulin degludec overdose follows a tiered approach that differs from short-acting insulin overdose primarily in duration.

Initial Stabilization

An IV line is placed immediately. Blood glucose, basic metabolic panel, and a toxicology screen are obtained. Dextrose 50% (D50W) in 25-50 mL boluses is given to raise glucose rapidly 5. The target is glucose between 100-180 mg/dL, not higher, because overshooting creates rebound hyperglycemia.

Sustained Dextrose Infusion

Because insulin degludec's action continues for up to 24-42 hours after an excess dose, a bolus alone is rarely sufficient. A continuous dextrose infusion (typically D10W at a rate adjusted to maintain target glucose) is standard for significant overdoses. Glucose must be checked every 30-60 minutes initially 5.

Observation Duration

The minimum observation period after a significant insulin degludec overdose should be at least 12-24 hours in a monitored setting, and 24-48 hours for large excess doses. This is longer than the typical 6-8 hours recommended for regular insulin overdose. Discharge is appropriate only when glucose has remained stable without IV dextrose for several hours.

Octreotide: When It Is Used

Octreotide, a somatostatin analogue that suppresses endogenous insulin secretion, is used in overdose from sulfonylureas, not from exogenous insulin, because it reduces the patient's own pancreatic insulin release. It has no direct effect on exogenous insulin degludec already in subcutaneous depot and is not a standard part of degludec overdose management 14.

Preventing an Accidental Excess Dose

Most insulin overdoses in clinical practice are errors, not intentional. Common causes include:

• Dose confusion between U-100 and U-200 formulations. Tresiba is available in both U-100 (FlexTouch pen, 100 units/mL) and U-200 (FlexTouch pen, 200 units/mL). Drawing U-200 into a syringe calibrated for U-100 delivers twice the intended dose 10. Always use the dedicated FlexTouch pen for the concentration prescribed. Never transfer Tresiba from a pen into a syringe.
• Double dosing. Because Tresiba's effect is flat and peakless, some patients are unsure whether they injected their dose and give a second one. Use a logbook, phone app, or the built-in dose memory on compatible pen devices.
• Stacking doses by changing injection timing. Tresiba can be given at any time of day, but shifting injection time by more than a few hours on back-to-back days can create transient dose overlap.
• Hormonal changes reducing insulin requirement. As described above, menstrual-phase transitions, early pregnancy nausea, or the immediate postpartum period can convert a stable dose into an accidental excess.

A 2023 systematic review in Diabetes Care found that insulin-related errors account for approximately 25% of medication errors in hospitalized patients, with basal insulin involved in a disproportionate share of severe events.

Evidence Gaps: What We Do Not Yet Know

Women have been underrepresented in large insulin pharmacokinetic studies. The multi-hexamer depot kinetics of insulin degludec were characterized primarily in studies with majority-male populations 1. Whether the half-life or coefficient of variation differs meaningfully by biological sex, body composition, or hormonal status has not been studied in well-powered trials. The DEVOTE trial enrolled 7,637 participants, of whom approximately 30% were women 13. Sex-stratified pharmacokinetic and hypoglycemia data from DEVOTE have not been published separately.

The practical takeaway: the 25-hour half-life figure and the overdose management durations used in this article are extrapolated from mixed-sex populations. Individual women, particularly those with significant hormonal fluctuations, may experience longer or shorter hypoglycemia windows than these averages predict.

As WomanRx medical reviewer Dr. Elena Vasquez, OB-GYN and diabetes specialist, explains: "The single most dangerous period for insulin overdose in a woman with type 1 diabetes is the 24-48 hours after delivery, when placental hormones vanish overnight and a basal insulin dose appropriate for the third trimester becomes massively excessive. Tresiba's long depot makes this window particularly treacherous. Every woman on basal insulin should have a written postpartum dose-reduction plan signed off by both her OB and her endocrinologist before her due date."